NCT04348448 is a clinical trial of Canakinumab 150 MG/ML [Ilaris] in COVID-19, sponsored by AUSL Romagna Rimini.

Who is sponsoring NCT04348448?

NCT04348448 is sponsored by AUSL Romagna Rimini.

What drugs are being tested in NCT04348448?

Interventions in NCT04348448: Canakinumab 150 MG/ML [Ilaris].

Is NCT04348448 still recruiting?

NCT04348448 is currently terminated. Last updated 21 July 2023.

Last reviewed 2023-07-21 · How we verify

NCT04348448

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

Terminated Last updated 21 July 2023

What this trial tests

trial testing Canakinumab 150 MG/ML [Ilaris] in COVID-19 in 100 participants. Terminated before completion.

Timeline

1 February 2020

Primary endpoint
1 May 2020

1 September 2020

Quick facts

Lead sponsor	AUSL Romagna Rimini
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 February 2020
Primary completion	1 May 2020
Estimated completion	1 September 2020
Sites	1 location across Italy

Drugs / interventions tested

Canakinumab 150 MG/ML [Ilaris] — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

AUSL Romagna Rimini — full company profile →

Who can join

Adults 18 to 100, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
Jamilloux Y, Henry T, Belot A, Viel S, et al · · 2020 · cited 486× · PMID 32376392 · DOI 10.1016/j.autrev.2020.102567
The signal pathways and treatment of cytokine storm in COVID-19.
Yang L, Xie X, Tu Z, Fu J, et al · · 2021 · cited 429× · PMID 34234112 · DOI 10.1038/s41392-021-00679-0
The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?
Darif D, Hammi I, Kihel A, El Idrissi Saik I, et al · · 2021 · cited 232× · PMID 33609650 · DOI 10.1016/j.micpath.2021.104799
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A, Smibert O, Gibson A, Phillips EJ, et al · · 2020 · cited 196× · PMID 32896310 · DOI 10.1016/j.jaci.2020.07.001
Controlling Cytokine Storm Is Vital in COVID-19.
Tang L, Yin Z, Hu Y, Mei H. · · 2020 · cited 123× · PMID 33329533 · DOI 10.3389/fimmu.2020.570993
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, et al · · 2020 · cited 93× · PMID 32468014 · DOI 10.3892/ijmm.2020.4608
Neutrophils in COVID-19: Not Innocent Bystanders.
McKenna E, Wubben R, Isaza-Correa JM, Melo AM, et al · · 2022 · cited 76× · PMID 35720378 · DOI 10.3389/fimmu.2022.864387
Development of therapeutic antibodies for the treatment of diseases.
Wang Z, Wang G, Lu H, Li H, et al · · 2022 · cited 69× · PMID 36418786 · DOI 10.1186/s43556-022-00100-4

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other AUSL Romagna Rimini trials

Trials by the same sponsor.

NCT07453927 — Blue Light for Donor Site Healing in Burn Patients · NA · recruiting
NCT07172061 — Sigh in Pressure Support Ventilation to Detect Respiratory System Compliance and Lung Recruitability · NA · completed
NCT06639100 — This Will Be an Observational, Exploratory Study Targeting a Population of Subjects with Diabetes from 4 Different Geogr · active not recruiting
NCT05306652 — Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment · NA · recruiting
NCT04839445 — ESP vs TAP in Total Laparoscopic Hysterectomy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04348448 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AUSL Romagna Rimini
Last refreshed: 21 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04348448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing